Results 201 to 210 of about 7,038,490 (299)

Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases. [PDF]

Breast Cancer Res
Rony R, Deng S, Yang S, Doig K, Goode DL.   +4 more
europepmc   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Translocated populations are genetically similar to natural populations and populations resulting from natural colonizations. [PDF]

PLoS One
Meléndez-Cal-Y-Mayor JF, Winkler J, Müller R, Lüscher B, Bolliger J, Ozgul A, Schmidt BR.   +6 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Genetic Relationship Analysis of <i>Pastor roseus</i> Based on <i>COI</i> and <i>Cytb</i> Gene Sequences. [PDF]

Ecol Evol
Sun X, Wang X, Li R, Liu H, Xu Y, Ji R, Lin J, Yang K, Ye X.   +8 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Glacial Legacies-How Refugial Dynamics Shaped the Evolution of the Alpine Endemic Bush-Cricket Anonconotus italoaustriacus. [PDF]

Mol Ecol
Kirschner P, Kranebitter P.
europepmc   +1 more source